CAR-20/19-T cells for Acute Lymphoblastic Leukemia (ALL)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute Lymphoblastic Leukemia (ALL)+5 MoreCAR-20/19-T cells - Biological
Eligibility
1 - 39
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study a new cancer treatment involving CAR-T cells, which are genetically modified to target and destroy cancer cells. The safety and effectiveness of this treatment will be evaluated in patients with B cell acute lymphoblastic leukemia.

Eligible Conditions
  • Acute Lymphoblastic Leukemia Recurrent
  • Acute Lymphoblastic Leukemia With Relapsed/Refractory Disease
  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Lymphoblastic Leukemia Not in Remission
  • Acute Lymphoblastic Leukemia (ALL) in Relapse

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CAR T-cell
1
UCART19 follow-up
1
BAFFR-CAR T cells

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 40 months

28 days after infusion
Number of Adverse Events after CAR 20/19-T Cell Infusion.
40 months
Describe the duration of response for responding patients.
Determine persistence of CAR-20/19-T cells.
Determine the anti-tumor responses as measured by response rates.
Determine the effects of CAR-20/19-T infusion on non-neoplastic CD19 & CD20 B cells in vivo.
Determine the feasibility to manufacture CAR-20/19-T cells locally from pediatric and young adult apheresis products using the CliniMACS Prodigy Cell processing device.
Determine the safety (dose level) of CAR-20/19-T cell administration in relapsed refractory B-ALL.
Evaluate MRD using molecular technologies.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
CAR T-cell
1
UCART19 follow-up
1
BAFFR-CAR T cells

Trial Design

6 Treatment Groups

Dose Escalation Phase
1 of 6
2.5 x10^5 CAR-20/19-T cells/kg
1 of 6
7.5 x10^5 CAR-20/19-T cells/kg
1 of 6
2.5 x10^6 CAR-20/19-T cells/kg
1 of 6
1 x 10^5 CAR-20/19-T cells/kg
1 of 6
Dose Expansion Phase
1 of 6

Experimental Treatment

24 Total Participants · 6 Treatment Groups

Primary Treatment: CAR-20/19-T cells · No Placebo Group · Phase 1

Dose Escalation Phase
Biological
Experimental Group · 1 Intervention: CAR-20/19-T cells · Intervention Types: Biological
2.5 x10^5 CAR-20/19-T cells/kg
Biological
Experimental Group · 1 Intervention: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) · Intervention Types: Biological
7.5 x10^5 CAR-20/19-T cells/kg
Biological
Experimental Group · 1 Intervention: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) · Intervention Types: Biological
2.5 x10^6 CAR-20/19-T cells/kg
Biological
Experimental Group · 1 Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) · Intervention Types: Biological
1 x 10^5 CAR-20/19-T cells/kg
Biological
Experimental Group · 1 Intervention: CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg) · Intervention Types: Biological
Dose Expansion PhaseExperimental Group · 5 Interventions: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg) · Intervention Types: Biological, Biological, Biological, Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
2017
Completed Phase 1
~30
CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)
2017
Completed Phase 1
~30
CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
2017
Completed Phase 1
~30

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 40 months

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
566 Previous Clinical Trials
1,154,136 Total Patients Enrolled
7 Trials studying Acute Lymphoblastic Leukemia (ALL)
2,706 Patients Enrolled for Acute Lymphoblastic Leukemia (ALL)
Children's Hospital and Health System Foundation, WisconsinOTHER
53 Previous Clinical Trials
96,125 Total Patients Enrolled
Julie-An Talano, MDPrincipal InvestigatorMedical College of Wisconsin
2 Previous Clinical Trials
85 Total Patients Enrolled

Eligibility Criteria

Age 1 - 39 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Subjects with B-cell ALL must have either CD19 or CD20 positive disease on their most recent bone marrow performed.
Subjects must be aged ≥1 year and ≤ 39 years with relapsed, refractory disease and no available curative options that meet clinical criteria to initiate treatment.
You have a primary refractory disease.
You have had two or more lines of systemic therapy for your disease.
The CD3+ T cell count in the peripheral blood is greater than 100/mm^3.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top